SCHEMBL16850583

SCHEMBL16850583

CC(=O)Oc1ccc(-c2ccc(-c3ccc(F)c(F)c3)cc2)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
GAA P10253 1/20 0.44
BACE1 P56817 3/20 0.44
HSD17B10 Q99714 1/20 0.44
APP P05067 2/20 0.43
CYP2C19 P33261 2/20 0.43
GAPDH P04406 1/20 0.43
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPC1 O15118 2/20 0.40
POLB P06746 1/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
GLA P06280 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748115 0.94 BACE1 (0.43) LMNAGAABACE1HSD17B10APP
SCHEMBL20296853 0.88 HSD17B10 (0.56) LMNAGAABACE1HSD17B10GAPDH
SCHEMBL12152596 0.86 BACE1 (0.47) LMNAGAABACE1HSD17B10APP
SCHEMBL21558697 0.85 BACE1 (0.59) LMNAGAABACE1HSD17B10APP
SCHEMBL31621879 0.84 LMNA (0.52) LMNAGAAHSD17B10MAPTTDP1
SCHEMBL823757 0.84 LMNA (0.52) LMNAGAAHSD17B10MAPTTDP1
SCHEMBL9903140 0.83 BACE1 (0.59) LMNAGAABACE1CYP2C19MAPT
SCHEMBL16604314 0.83 LMNA (0.42) LMNAGAABACE1HSD17B10APP
SCHEMBL16748079 0.83 APP (0.39) APPCYP2C19CYP3A4CYP2C9
SCHEMBL21507746 0.82 HSD17B10 (0.44) LMNAGAABACE1HSD17B10APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3248061-B1 LIGHT MODULATION ELEMENT MERCK PATENT GMBH (DE) 2020-10-14 EP disclosed
EP-3248060-B1 LIGHT MODULATION ELEMENT MERCK PATENT GMBH (DE) 2020-09-02 EP disclosed
US-20200255739-A1 LIGHT MODULATION ELEMENT MERCK PATENT GMBH (DE) 2020-08-13 US disclosed
US-20200181492-A1 LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DEVICE MERCK PATENT GMBH (DE) 2020-06-11 US disclosed
US-10669484-B2 Process of preparing a light modulation element MERCK PATENT GMBH (DE) 2020-06-02 US disclosed
EP-3365411-B1 LIGHT MODULATION ELEMENT MERCK PATENT GMBH (DE) 2020-05-13 EP disclosed
EP-3234689-B1 LIGHT MODULATION ELEMENT MERCK PATENT GMBH (DE) 2020-01-29 EP disclosed
US-20190292457-A1 LIGHT MODULATION ELEMENT MERCK PATENT GMBH (DE) 2019-09-26 US disclosed
WO-2019179962-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2019-09-26 WO disclosed
WO-2019030153-A1 LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DEVICE MERCK PATENT GMBH (DE) 2019-02-14 WO disclosed
US-20170357131-A1 LIGHT MODULATION ELEMENT MERCK PATENT GMBH (DE) 2017-12-14 US disclosed
US-20170351130-A1 LIGHT MODULATION ELEMENT MERCK PATENT GMBH (DE) 2017-12-07 US disclosed
US-20170343847-A1 LIGHT MODULATION ELEMENT MERCK PATENT GMBH (DE) 2017-11-30 US disclosed
WO-2017198635-A1 LIGHT MODULATION ELEMENT MERCK PATENT GMBH (DE) 2017-11-23 WO disclosed
US-9752075-B2 Mesogenic media and liquid crystal display MERCK PATENT GMBH (DE) 2017-09-05 US disclosed
US-20170190971-A1 MESOGENIC MEDIA AND LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2017-07-06 US disclosed
WO-2017067630-A1 LIGHT MODULATION ELEMENT MERCK PATENT GMBH (DE) 2017-04-27 WO disclosed
US-20160298031-A1 MESOGENIC MEDIA AND LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2016-10-13 US disclosed
US-20160289561-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MERCK PATENT GMBH (DE) 2016-10-06 US disclosed
US-20150175886-A1 MESOGENIC MEDIA AND LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2015-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160289561-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA SP1, FOXM1, S100A11 LMNA 1318/4885GAA 4685/4885BACE1 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.